Drugmakers will likely have tens of millions of doses of coronavirus vaccines in the early part of next year, Anthony Fauci, the top U.S. infectious diseases official, said in a Reuters interview.
Russia’s minister of health, Mikhail Murashko, indicated that the country is planning a nationwide program to vaccinate its population against Covid-19 starting in October.
U.S. drugmaker Eli Lilly & Co. is beginning a late-stage trial to study whether one of the company’s experimental Covid-19 antibody treatments can prevent the spread of the virus in residents and staff at U.S. nursing homes.
Moderna Inc. and Pfizer Inc. launched two 30,000-subject trials of Covid-19 vaccines that could clear the way for regulatory approval and widespread use by the end of 2020.
The United States shattered the country’s daily record for coronavirus infections on Thursday, reporting more than 77,000 new cases as the number of deaths in a 24-hour period rose by nearly 1,000, according to a Reuters tally.
Moderna Inc.’s experimental vaccine for Covid-19 showed mRNA-1273 was safe and provoked immune responses in all 45 healthy volunteers in an ongoing early-stage study, U.S. researchers reported.
The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.
Regeneron Pharmaceuticals – with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) – is launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19.
Emergent BioSolutions entered a five-year manufacturing services deal with Janssen Pharmaceutical to manufacture Johnson & Johnson’s Ad26.COV2-S COVID-19 vaccine.
COVID-19 vaccine candidates will enter late-stage clinical studies by the end of the month, with others beginning in August, September and October, the U.S. government’s top infectious diseases expert said.
